Cipla Ltd.

BSE: 500087 | NSE: CIPLA
Large Cap | Pharmaceuticals & Drugs
1390.90
7.90 (0.57%)
< Home < Back

USFDA classifies Cipla’s Bengaluru manufacturing facility as Voluntary Action Indicated

Date: 10-02-2025

United States Food and Drugs Administration (USFDA) has classified routine current Good Manufacturing Practices (cGMP) inspection conducted at Cipla’s Bengaluru manufacturing facility, as Voluntary Action Indicated (VAI). USFDA had conducted routine current Good Manufacturing Practices inspection at Cipla’s said facility from November 07 to November 13, 2024. 

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.